ArticleJournal of translational medicine2026
Untargeted metabolomics identifies altered metabolome contributing to hypertension in late adolescents.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceChildhood hypertension is a growing health problem, yet its specific biomarkers are not yet fully elucidated.
objectiveThe aim of this study was to investigate the functional metabolic alteration associated with hypertension in late adolescents.
designThis study employed a cluster random sampling method based on the Health Promotion Program for Children and Adolescents. In the first stage in 2020-2021, three schools were selected for hypertension screening, followed by four schools in the second stage in 2022-2023. Hypertensive students in their late adolescent were matched 1:1 with normotensive controls for an untargeted metabolomics study to identify differential metabolites. In vitro cellular experiments were further performed to explore the functional roles of the interested metabolite.
settingTwo separate case-control studies and cellular experiments.
participantsIn the first stage, a total of 51 late adolescents were identified with hypertension, and then were matched with 51 normotensive controls of similar sex and age from the same dormitory to collect their fasting urine samples. In the second stage, 91 hypertensive adolescents were identified and 91 matched normotensive adolescents were selected from the same dormitory to collect their fasting serum samples. MAIN OUTCOMES AND MEASURES: Hypertension was diagnosed by blood pressure measurements taken on three separate occasions.
resultsDetailed metabolomic evaluation revealed four distinct metabolites differentially expressed in hypertensive adolescents and control individuals in both urine and serum samples. As compared with the control group, higher levels of 2-hydroxycinnamic acid and xanthine, but lower levels of hypoxanthine and N-acetylornithine were observed in hypertensive adolescents. These metabolites also slightly enhance the discriminatory ability for hypertension based on body mass index Z score, as revealed by increased area under receiver operating characteristic curve. Notably, 2-hydroxycinnamic acid could inhibit cell proliferation, induce oxidative stress and inflammatory responses, and then disrupt the cellular function of human umbilical vein endothelial cells, inferring it as a potential detrimental metabolite for hypertension in adolescents. CONCLUSIONS AND RELEVANCE: Our result revealed distinct metabolic alterations in urine and serum samples of hypertensive adolescents. Combined with metabonomic and in vitro experiments, 2-hydroxycinnamic acid was identified as a potential detrimental metabolite for hypertension in adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.